Wells Fargo lowered the firm’s price target on PTC Therapeutics (PTCT) to $86 from $93 and keeps an Overweight rating on the shares. The firm was encouraged by commentary on the Sephience refill rate, and expects this to be a tailwind. Wells thinks some deceleration is likely, but model positive growth on the assumption of greater penetration within key centers.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics: Sephience Uptake, Advancing Pipeline, and Strengthening Financials Support Buy Rating
- Balanced Outlook on PTC: Sephience-Driven Growth Offset by Duchenne Headwinds and Unmodeled Vatiquinone Upside Supports Hold Rating
- PTC Therapeutics Tops 2025 Revenue Guidance, Boosts Cash
- PTC Therapeutics reports Q4 EPS ($1.67), consensus (41c)
- PTC Therapeutics sees 2026 product revenue up 19%-36%to $700M-$800M